UOC
HUMA icon

UBS O'Connor’s Humacyte HUMA Stock Holding History

UBS O'Connor’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-595,172
Closed -$1.94M – 792
2022
Q3 		$1.94M Sell
595,172
-504,828
-46% -$1.94M 0.02% 632
2022
Q2 		$3.53M Sell
1,100,000
-184,029
-14% -$1.02M 0.04% 432
2022
Q1 		$9.06M Buy
1,284,029
+383,929
+43% +$2.24M 0.1% 103
2021
Q4 		$6.53M Buy
+900,100
New +$8.9M 0.06% 142
2021
Q3 		– Sell
-300,000
Closed -$3.06M – 950
2021
Q2 		$3.06M Sell
300,000
-3,800
-1% -$39.1K 0.03% 380
2021
Q1 		$3.29M Buy
+303,800
New +$3.32M 0.05% 364

Other funds holding HUMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

UBS O'Connor's HUMA Position: Q4 2022 in Review

UBS O'Connor sold out of Humacyte (HUMA) in Q4 2022, closing a stake of 595,172 shares — an estimated $1.94M sold.

UBS O'Connor first reported a position in HUMA in Q1 2021 and held it in 6 quarters. The position peaked at $9.06M in Q1 2022. 75 funds tracked by Wall St. Rank hold HUMA as of Q4 2022.

  • UBS O'Connor reported no remaining Humacyte position as of Q4 2022 after selling out during the quarter.
  • UBS O'Connor sold 595,172 Humacyte shares in Q4 2022, an estimated $1.94M.
  • UBS O'Connor first reported a position in Humacyte in Q1 2021 and held it in 6 quarters.
  • UBS O'Connor's Humacyte position peaked at $9.06M in Q1 2022.
  • 75 funds tracked by Wall St. Rank held Humacyte as of Q4 2022.

Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.